Table 1. Clinical and laboratory characteristics of patients with AML with DNMT3A mutations from the 12 included studies.
| First author | Year | Source | NOS | n/N | Median follow-up, mo (range) | Median age, y (range) | FAB classification | Cytogenetic risk group | HR estimation |
| Timothy J. Ley | 2010 | USA | 9 | 62/281 | 34.1 (0.2–129.3) | 53.1 (39.4–66.8) | M0, 2; M1, 15; M2, 11; M3, 1; M4, 20; M5, 12; M6, 0; M7, 1; RAEB, 0; Unknown, 0 | Favorable, 0; Intermediate, 56; Adverse, 4; Unknown, 2 | HR |
| Yang Shen | 2011 | China | 7 | 75/1141 | — | 38–69 | — | — | HR |
| Felicitas Thol | 2011 | Germany | 9 | 87/489 | 61.2 (0.624–140.4) | 52 (30–60) | M0, 3; M1, 15; M2, 8; M3, 0; M4, 37; M5, 22; M6, 1; M7, 0; RAEB, —; Unknown, 1 | Favorable, 1; Intermediate, 82; Adverse, 4; Unknown, 0 | HR |
| Hsin-An Hou | 2011 | Taiwan | 8 | 70/500 | 55 (1.0–160) | 61 (16–87) | M0, 2; M1, 14; M2, 13; M3, 0; M4, 28; M5, 12; M6, 0; M7, —; RAEB, —; Unknown, 1 | Favorable, 0; Intermediate, 62; Adverse, 4; Unknown, 4 | HR |
| Jana Markova | 2011 | Czech Republic | 5 | 67/226 | 11.6 (0–202) | 54.9 (18.2–81.7) | M0, 0; M1, 18; M2, 22; M3, —; M4, 17; M5, 5; M6, —; M7, —; RAEB, —; Unknown, 5 | Favorable, 0; Intermediate, 67; Adverse, 0; Unknown, 0 | Survival curve |
| A Renneville | 2012 | France | 7 | 36/123 | 46.8 | 47 (23–58) | M0, 0; M1, 6; M2, 10; M3, 0; M4, 11; M5, 9; M6, 0; M7, 0; RAEB, 0; Unknown, 0 | Favorable, 0; Intermediate, 36; Adverse, 0; Unknown, 0 | HR |
| Guido Marcucci | 2012 | USA | 9 | 142/415 | 90 (27.6–488) | 61 (22–82) | M0, 1; M1, 29; M2, 18; M3, 0; M4, 33; M5, 26; M6, 0; M7, —; RAEB, —; Unknown, 35 | Favorable, 0; Intermediate, 142; Adverse, 0; Unknown, 0 | HR |
| Jay P. Patel | 2012 | USA | 9 | 88/384 | — | 48 (17–60) | — | — | HR |
| Ana Flávia Tibúrcio Ribeiro | 2012 | USA | 9 | 96/415 | 115.7 (7.2–224.1) | 50.5 (18–60) | M0, 1; M1, 15; M2, 23; M3, —; M4, 15; M5, 36; M6, 1; M7, —; RAEB, 3; Unknown, 2 | Favorable, 0; Intermediate, 85; Adverse, 6; Unknown, 5 | HR |
| Xu, Y | 2012 | China | 5 | 31/442 | — | 40 (16–60) | — | — | HR |
| Ostronoff, F | 2013 | USA | 6 | 37/191 | 101.6 | 68 (57–81) | M0, 2; M1, 9; M2, 6; M3, 0; M4, 10; M5, 7; M6, 0; M7, 0; RAEB, 0; Unknown, 3 | Favorable, 0; Intermediate, 24; Adverse, 1; Unknown, 12 | HR |
| Verena I. Gaidzik | 2013 | Germany | 9 | 370/1770 | 59.28 | 50.5 (18–60) | — | Favorable, 4; Intermediate, 309; Adverse, 33; Unknown, 24 | HR |
NOS, Newcastle-ottawa quality assessment scale; n, number of patients with DNMT3A mutations; N, number of patients in total; —, indicates there is no related data presented.